Skip to main content
Clinical Trials/NCT05556031
NCT05556031
Not yet recruiting
Not Applicable

The Reduction of Decompensation and Unnecessary Cardiac Failure Emergency Admissions: Ambulatory Heart Failure Service Model

Chinese University of Hong Kong1 site in 1 country500 target enrollmentOctober 2022
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Chinese University of Hong Kong
Enrollment
500
Locations
1
Primary Endpoint
Clinical outcome
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

The aim of the study is to assess the efficacy of this new ambulatory service model in reducing heart failure hospitalization (HHF), improving clinical as well as functional outcomes of post-discharge patients with Heart Failure of reduced ejection fraction (HFrEF) and Heart failure with preserved Ejection Fraction (HFpEF).

Registry
clinicaltrials.gov
Start Date
October 2022
End Date
January 2028
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Professor Bryan Ping Yen YAN

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • Dyspnoea (exertional or at rest) and 2 of the following signs:
  • Congestion on chest X-ray
  • Rales on chest auscultation
  • Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale)
  • Elevated jugular venous pressure
  • NT-proBNP ≥300 pg/mL (Patients with AF: NT-proBNP ≥900 pg/mL)
  • Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v loop diuretics)
  • Ambulatory patients

Exclusion Criteria

  • Cardiogenic shock required inotropics
  • Cardiac mechanical support implantation like LVAD
  • Life expectancy less than 1 year due to underlying significant comorbidities like metastatic cancer or end-stage COPD
  • Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study.
  • End stage renal failure or eGFR \<15 mL/min/1.73m2 as measured during index hospitalization or requiring dialysis

Outcomes

Primary Outcomes

Clinical outcome

Time Frame: 90 days

A composite of all-cause mortality, number of heart failure events (including hospitalization for heart failure (HHF), urgent heart failure visits and unplanned outpatient visits), time to first heart failure event will be aggregated to evaluate overall clinical outcome

Secondary Outcomes

  • Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)(1 year)
  • NT-proBNP level(1 year)
  • Risk of Heart failure(1 year)
  • Quality adjusted Life years gained(1 year)
  • Change in overall Cardiac function(90 days)
  • Major Adverse Cardiovascular Event(1 year)
  • Hypertensive heart failure (HHF)(90 days after initial hospital discharge)
  • Change in 6 minute hall walk (6MHW)(90 days)

Study Sites (1)

Loading locations...

Similar Trials